



Nutrition Society Live 2020 was held virtually on 14–15 July 2020

Symposium one: Metabolic health

Dietary protein, exercise, ageing and physical inactivity: interactive influences on skeletal muscle proteostasis

Colleen S. Deane^{1,2}, Isabel A. Ely³, Daniel J. Wilkinson³, Kenneth Smith³, Bethan E. Phillips³ and Philip J. Atherton^{3*}

¹Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, Exeter EX1 2LU, UK

²Living Systems Institute, University of Exeter, Stocker Road, Exeter EX4 4QD, UK

³MRC Versus Arthritis Centre for Musculoskeletal Ageing Research & NIHR Nottingham Biomedical Research Centre, University of Nottingham, Royal Derby Hospital Centre, Derby DE22 3DT, UK

Dietary protein is a pre-requisite for the maintenance of skeletal muscle mass; stimulating increases in muscle protein synthesis (MPS), via essential amino acids (EAA), and attenuating muscle protein breakdown, via insulin. Muscles are receptive to the anabolic effects of dietary protein, and in particular the EAA leucine, for only a short period (i.e. about 2–3 h) in the rested state. Thereafter, MPS exhibits tachyphylaxis despite continued EAA availability and sustained mechanistic target of rapamycin complex 1 signalling. Other notable characteristics of this ‘muscle full’ phenomenon include: (i) it cannot be overcome by proximal intake of additional nutrient signals/substrates regulating MPS; meaning a refractory period exists before a next stimulation is possible, (ii) it is refractory to pharmacological/nutraceutical enhancement of muscle blood flow and thus is not induced by muscle hypo-perfusion, (iii) it manifests independently of whether protein intake occurs in a bolus or intermittent feeding pattern, and (iv) it does not appear to be dependent on protein dose *per se*. Instead, the main factor associated with altering muscle full is physical activity. For instance, when coupled to protein intake, resistance exercise delays the muscle full set-point to permit additional use of available EAA for MPS to promote muscle remodelling/growth. In contrast, ageing is associated with blunted MPS responses to protein/exercise (anabolic resistance), while physical inactivity (e.g. immobilisation) induces a premature muscle full, promoting muscle atrophy. It is crucial that in catabolic scenarios, anabolic strategies are sought to mitigate muscle decline. This review highlights regulatory protein turnover interactions by dietary protein, exercise, ageing and physical inactivity.

Dietary protein: Exercise: Ageing: Physical inactivity: Proteostasis

A prominent feature of many communicable infectious, non-communicable and non-disease-related conditions, such as ageing⁽¹⁾, cancer⁽²⁾, diabetes⁽³⁾, rheumatoid arthritis⁽⁴⁾, physical inactivity⁽⁵⁾ and bed-rest/immobilisation⁽⁶⁾, is the undesirable loss of skeletal muscle mass (atrophy). As

the largest organ in the body occupying about 45–55% of body mass, skeletal muscle plays pivotal roles in locomotion, structural support and metabolic health, serving as the largest reservoir of amino acids (AA)⁽⁷⁾ and acting as a key storage site for glucose and intramuscular lipids for

Abbreviations: AA, amino acids; BCAA, branched-chain amino acids; EAA, essential amino acids; eIF, eukaryotic initiation factor; HMB, β-hydroxy-β-methylbutyrate; KIC, α-ketoisocaproate; MPB, muscle protein breakdown; MPS, muscle protein synthesis; mTORC1, mechanistic target of rapamycin complex 1; NEAA, non-essential amino acids; RE, resistance exercise; RET, resistance exercise training; 1-RM, 1-repetition maximum.

*Corresponding author: Philip J. Atherton, email Philip.Atherton@nottingham.ac.uk

energy production^(8,9). As such, maintenance of a healthy muscle mass is critical to whole-body health and well-being across the lifespan⁽¹⁰⁾. It therefore follows that the consequences of muscle atrophy are not trivial; demonstrable by robust associations with numerous negative health-related outcomes^(11,12), such as an increased risk of frailty-related falls⁽¹³⁾, morbidity⁽¹⁴⁾ and even mortality⁽¹⁵⁾.

The intake of dietary protein is a pre-requisite for the day-to-day maintenance of skeletal muscle mass, whereby muscle protein breakdown (MPB) exceeds muscle protein synthesis (MPS) in the fasted state and MPS exceeds MPB in the fed state (and so MPS and MPB are equal across diurnal fasted-fed cycles⁽¹⁶⁾). Indeed, the quantity and composition of dietary protein are factors known to dictate the anabolic response^(16,17); namely the magnitude and duration of MPS and MPB. In certain (patho)physiological conditions, the anabolic response to dietary protein/exercise can be heightened or impaired. For example, in response to exercise, both MPS and MPB are transiently increased, where protein provision means MPS is enhanced while MPB is put under restraint, contributing to a positive net protein balance, therein driving skeletal muscle growth (hypertrophy)⁽¹⁶⁾. On the contrary, during ageing and/or physical inactivity, dietary protein can fail to robustly stimulate MPS, contributing to negative net protein balance and driving muscle atrophy. As such, interactions between dietary protein and muscle metabolism remain an area of intense research, driven by a clinical need to identify countermeasures against atrophy, but also in light of the emerging need for sustainable protein sources of high-biological value⁽¹⁸⁾.

Previous reviews have discussed the regulation of human skeletal muscle protein metabolism by dietary protein, yet such reviews are often more singularly focused e.g. on protein quantity (e.g.⁽¹⁹⁾), protein quality (e.g.⁽¹⁷⁾), the exercise stimulus (e.g. resistance exercise (RE)^(20,21)) or population (e.g. ageing⁽²²⁾) in isolation or myriad aspects of dietary protein modulation (i.e. dose, quantity) in human subjects *per se* (i.e. not population specific (e.g.⁽¹⁶⁾). This review focuses upon the anabolic effects of dietary protein, including quantity and quality/composition, in the context of: (i) exercise, (ii) ageing, (iii) physical inactivity and (iv) physical inactivity during ageing, as conditions which can significantly influence the anabolic response to protein feeding. As such, this review will mainly be of interest to scientists, nutritionists, dietitians and clinicians interested in frameworks about protein feeding to potentiate muscle health in situations of exercise, and offset muscle decline in situations of ageing and inactivity (e.g. hospitalisation). Out of the scope of this review is discussion regarding methodologies used to quantify human skeletal muscle protein metabolism (e.g. stable isotope tracers) and so we direct readers to the following in-depth focused publications^(23–28).

Dietary protein induces transient muscle anabolism until ‘muscle full’

The anabolic effects of feeding, which are driven by the transfer and incorporation of AA obtained from dietary

sources into skeletal muscle proteins⁽¹⁶⁾, were realised >30 years ago when the provision of a mixed-macronutrient meal (containing protein, carbohydrate and fat) was shown to stimulate acute MPS in human subjects⁽²⁹⁾. It later transpired this robust MPS stimulation is highly dependent on the AA content of the meal⁽³⁰⁾, which was uniquely attributed to the essential amino acids (EAA)^(31,32). This was eloquently demonstrated where bolus feeding of EAA (e.g. leucine, phenylalanine, threonine) stimulated MPS, but non-essential amino acids (NEAA; e.g. arginine, glycine, serine) did not^(31,32). This AA-induced stimulation of MPS is purportedly dose-dependent with maximal anabolic stimulation being achieved with about 10–20 g EAA⁽³³⁾ or about 20–40 g high-quality protein^(34–38). However, of all EAA, the branched-chain amino acid (BCAA), leucine, can robustly stimulate MPS in isolation⁽³⁹⁾, and so it is likely that the dose–response of MPS to protein/EAA is not driven by AA quantity *per se* but instead by the leucine content⁽⁴⁰⁾. Reflecting this, it was shown that 3 g EAA containing 40% leucine elicited comparable MPS to that of 20 g whey in older women⁽⁴⁰⁾. An important implication of this is that low doses of leucine-enriched EAA may provide less satiating yet anabolically robust nutritional protein sources (which is particularly relevant for older adults where the satiety of a feed is a key consideration^(40,41)). The digestion rate of the protein source is also purported to determine the subsequent anabolic impact, whereby ‘fast’ (e.g. whey) proteins result in rapid aminoacidemia and greater protein accretion compared to ‘slow’ (e.g. casein) proteins. Whilst there is data to show that 20 g whey elicits a greater MPS response *v.* a matched dose of casein, it is important to note that these protein sources differed in AA constituency, particularly in leucine content^(42,43). Consequently, to address the importance of the EAA delivery profile upon muscle anabolism, Mitchell *et al.* provided older males with EAA consumed as either a single 15 g bolus (eliciting rapid aminoacidemia) or in four smaller pulse doses of 3.75 g received every 45 min (eliciting slower aminoacidemia), and demonstrated no differences in MPS⁽⁴⁴⁾. As such, it is plausible to suggest that the content of leucine is a major determinant of the ensuing anabolic response. However, it should be noted that although leucine stimulates MPS in the absence of other AA via depletion of endogenous intra-myocellular pools, MPS would eventually become limited by the availability of other EAA⁽²⁰⁾ i.e. as an extreme example, if one were to replace protein in meals to leucine alone. In addition to acting as a signal and substrate for MPS, as a BCAA, and along with other BCAA (isoleucine and valine)⁽⁴⁵⁾, leucine may also be metabolised within skeletal muscle. This occurs via BCAA deamination and decarboxylation with ensuing metabolic steps leading to the formation of derivative molecules which feed into myriad metabolic pathways, such as the tricarboxylic acid cycle. On this basis, it has been suggested that BCAA metabolites may possess anabolic properties beyond the intact BCAA⁽⁴⁶⁾. Indeed, α -ketoisocaproate (KIC), which is the resultant keto-acid from leucine transamination, stimulates comparable MPS rates to leucine, albeit not in human muscle⁽⁴⁷⁾.

However, plasma leucine concentrations increase with KIC infusion and the reversible transamination of KIC back to leucine may mean that leucine was accountable for the stimulation of MPS⁽⁴⁶⁾. Whilst the KIC-branched-chain α -keto acid dehydrogenase pathway is the fate of most leucine metabolism, a minority (5%) is converted to the metabolite, β -hydroxy- β -methylbutyrate (HMB)⁽⁴⁸⁾ via KIC dioxygenase. Although primarily involved in cholesterol synthesis, HMB possesses robust anabolic and anti-catabolic properties^(39,46,49), demonstrated by the provision of 3 g free acid-HMB stimulating MPS, similar to that of leucine, while also suppressing MPB in young human subjects^(39,49). Importantly, despite proposed differences in bioavailability, the pro-anabolic and anti-catabolic properties of HMB also extend to the calcium salt form of HMB⁽⁴⁹⁾.

Notably, skeletal muscles are receptive to the anabolic effects of AA for only a short period in the rested state; thus exhibiting temporal regulation. Following feeding, there is an initial lag of about 45–90 min post AA intake due to the time taken for digestion, absorption, arrival at the target tissue (i.e. muscle capillary perfusion and crossing the interstitium) and activation of intracellular anabolic signalling pathways⁽¹⁶⁾. Subsequently, MPS increases about 2–3-fold, peaking between about 1.5–2 h, prior to returning to baseline a total of about 2–3 h later⁽¹⁶⁾. Thereafter, MPS displays tachyphylaxis despite continued EAA availability and elevated intracellular anabolic signalling⁽⁵⁰⁾, a phenomenon termed muscle full⁽⁵¹⁾, whereby muscle cells intrinsically sense excess EAA and divert them away from incorporation into muscle proteins, instead towards oxidation^(23,37). The notion that MPS may not be continually stimulated by dietary protein intake is reflected by the fact that dietary protein alone, even in excess, cannot induce muscle hypertrophy⁽⁴⁶⁾. Despite this muscle full phenomenon, the mechanisms regulating MPS-related tachyphylaxis despite adequate EAA provision and appropriate intracellular signalling remain elusive, although may reflect attenuated translation elongation^(52,53) or endoplasmic reticulum stress⁽⁴⁶⁾. Another notable characteristic of the muscle full state is the fact that it cannot be overcome by proximal intake of additional nutrient signals/substrates regulating MPS (i.e. leucine)⁽⁵⁴⁾. Therefore, a refractory period must exist before a further stimulation of MPS is possible, although the precise kinetics (i.e. duration, etc.) of this period remain ill-defined. Finally, muscle full is also refractory to pharmacological and nutraceutical enhancement of nutritive muscle blood flow, demonstrated by vasodilatory methacholine⁽⁵⁵⁾ and cocoa flavanols⁽⁵⁶⁾ having no added effects on MPS despite enhancing leg blood flow and microvascular blood volume; as such muscle full is not a state induced by muscle hypo-perfusion. Finally, muscle full manifests independently of whether protein intake occurs in a bolus or intermittent feeding pattern⁽⁴⁴⁾, thus suggesting differing rates of aminoacidemia (and dose-dependence) do not dictate muscle full.

Whilst being substrates for MPS, certain EAA also act as key signalling molecules regulating MPS responses⁽⁴⁶⁾.

Following *trans*-sarcolemmal EAA transport, leucine (and perhaps other EAA) activates the mechanistic target of rapamycin complex-1 (mTORC1), independent of proximal insulin (e.g. PI3 K/AKT) signalling⁽¹⁶⁾. mTORC1 activation induces phosphorylation of 4E-binding protein and ribosomal protein S6 kinase, stimulating the binding of the eukaryotic initiation factor (eIF) 4A and eIF4E to eIF4G, forming the eIF4F complex⁽⁵⁷⁾. Thereafter, the eIF4F complex mediates mRNA binding to the 43S preinitiation complex, ultimately resulting in the formation of the 48S preinitiation complex⁽⁵⁷⁾. This relay system triggered by intracellular EAA accumulation results in an upregulation in rates of mRNA translation and thus, MPS. Whilst the EAA-induced upstream regulation of mTORC1 is incompletely defined, recent evidence suggests leucine binding to Sestrin-2 (an intracellular leucine sensor of the mTOR pathway) and subsequent dissociation of Sestrin-2 and the GTPase-activating protein, GATOR2, leads to mTORC1 activation⁽⁵⁸⁾. For more in-depth discussions on nutrient-led signalling to MPS, readers are encouraged towards the following reviews^(57,59,60).

In addition to stimulating MPS, protein/EAA intake (with or without carbohydrate) provides a second route for anabolism via suppression of MPB. This is a facet of nutrient-mediated protein accretion which is entirely attributable to insulin action⁽¹⁶⁾. Illustrating this, insulin at 3 \times postabsorptive concentrations (i.e. about 15 μ U/ml) was sufficient to inhibit MPB by about 50%⁽⁶¹⁾; an observation which could not be recapitulated by the provision of EAA infusions during postabsorptive insulin clamps (i.e. at 5 μ U/ml)⁽⁶²⁾. Thus, since the provision of protein/AA only suppresses MPB when insulin is allowed to rise above post-absorptive levels⁽⁶²⁾, it is insulin and not EAA that is responsible for the anti-catabolic effects of feeding⁽⁶¹⁾. Supporting this, a recent systematic review and meta-analysis of >40 human studies concluded insulin has a permissive role in MPS but does not have a prominent anti-catabolic role in attenuating MPB⁽⁶³⁾. Nonetheless, changes in MPS are likely to be greater than those of MPB (at least in healthy muscle), and so MPS remains the key driver of protein feeding-induced anabolism⁽¹⁶⁾.

Dietary protein and exercise interactions delay the onset of muscle full

In addition to being a prerequisite for skeletal muscle maintenance, dietary protein is critical for the ensuing muscle adaptation in response to RE. This is evidenced by the fact that exercise-induced increases in MPS in the absence of protein/EAA result in a prolonged elevation in MPB, therein contributing to an overall negative muscle protein balance⁽⁶⁴⁾. As such, exercise must be coupled with sufficient protein/EAA in order to achieve positive net protein balance, yielding small amounts of muscle protein accrual after each individual bout of RE, that ultimately culminate over a period of resistance exercise training (RET) resulting in muscle hypertrophy⁽²⁰⁾.

A prominent feature of exercise is that it increases the anabolic sensitivity of the muscle therein delaying the

onset of muscle full. Specifically, increasing the availability of dietary EAA post-exercise enhances the magnitude and duration of the MPS response⁽⁶⁵⁾, with no further anabolic effects (i.e. increase in MPS and/or decrease in MPB) evidenced with the addition of carbohydrates⁽⁶⁶⁾. To further evidence this, older women exhibited comparable increases in MPS for 2 h following whey or low-dose leucine-enriched EAA feeding in the absence of exercise, whereas exercise (i.e. RE) combined with protein feeding (regardless of composition) prolonged this response, stimulating MPS for 4 h⁽⁴⁰⁾. In some cases, these exercise-enhanced MPS responses to protein intake can last for 24 h⁽⁶⁷⁾. The maximisation of the post-exercise MPS response also relates to studies investigating the optimal timing of protein intake in and around exercise. However, considering an acute bout of RE delays muscle full considerably (i.e. up to 24 h⁽⁶⁷⁾), nutrient consumption pre-, during or post-exercise is perhaps not as critical as presumed; and rather, protein sufficiency (that being quantity and quality) is the most fundamental consideration⁽¹⁶⁾. Despite exercise sensitising the muscle to protein feeding, limits still exist whereby muscle full is still reached. Specifically, in response to unilateral leg-based RE, MPS displays a dose–response relationship to dietary protein ingestion until maximal stimulation with 20 g intact protein, where doses above which (i.e. 40 g) lead to irreversible oxidation and thus excess protein is catabolised^(16,35). However, in situations of whole-body RE the protein requirements tend to be greater where 40 g whey protein stimulated MPS to a greater extent than 20 g, although the dose needed to reach muscle full was not determined⁽³⁸⁾. Taken together, protein-intake coupled with RE delays, but does not fully overcome an eventual muscle full, to permit additional use of available EAA for MPS to promote appropriate muscle remodelling and/or growth.

Older skeletal muscle displays ‘anabolic resistance’ to dietary protein intake and exercise (i.e. resistance exercise)

For more than a decade, work developing the concept of ‘anabolic resistance’ has greatly aided explanation of age-related declines in skeletal muscle mass⁽⁶⁸⁾. Although some early, small cohort studies reported depressed basal (post-absorptive, rested) MPS rates in older compared to younger age^(69,70), it is now largely accepted that post-absorptive rates of MPS and MPB are unchanged in healthy ageing^(22,34,71,72). Anabolic resistance, therefore, centres upon the blunting of increases in MPS and/or suppression of MPB to key anabolic drivers, namely exercise and nutrition^(34,71–73). Reflecting this, a plethora of accumulating evidence (i.e.^(34,71–75)) suggests that anabolic resistance is likely a major driver of age-related muscle atrophy (sarcopenia); though that is not to say mixed results engender this contentious^(36,76). Seminal work by Cuthbertson *et al.* demonstrated a maximal MPS response in young adults to 10 g EAA, with older adults having suppressed rates of MPS above 5 g EAA⁽³³⁾. Furthermore, a 40 g bolus of EAA failed to elicit a similar MPS response in older adults to that seen in young adults at 10 g EAA⁽³³⁾.

Two recent meta-analyses further support the existence of anabolic resistance in aged muscle, with Wall *et al.* reporting depressed post-prandial MPS rates (–16%) in older adults⁽⁷²⁾ and Moore *et al.* reporting a ‘rightward shift’ whereby myofibrillar fractional synthesis rate (i.e. MPS) plateaus with respect to relative protein intake in older (about 0.4 g/kg) compared to young (about 0.24 g/kg) men⁽³⁴⁾.

Fortifying protein with leucine may provide another nutraceutical avenue for combating anabolic resistance in ageing muscle. Older adults typically exhibit increased satiety after consuming a meal⁽³³⁾, which likely contributes to the inadequate daily consumption of protein (RDA: 1.0–1.2 g/kg BW/d⁽⁷⁷⁾) commonly seen in the older population^(33,73). As such, specific EAA, such as leucine, may be considered as an adjuvant nutritional strategy to maximise MPS that can also alleviate satiating effects⁽⁷³⁾. Through the consumption of a submaximal protein drink (10 g) enriched with 4.5 g leucine, older adults exhibited elevated MPS (0.14 (SEM 0.01) %/4 h), compared to enrichment with 4.5 g alanine (0.11 (SEM 0.01) %/4 h), with fractional synthesis rate remaining elevated above baseline beyond the measured 4 h⁽⁷⁸⁾. Moreover, anabolic signalling was robustly triggered when administering about 6 g BCAA (about 2.6 g leucine), hence leading to an increase in acute MPS response in both young muscle post-RE⁽⁷⁹⁾ and in older adults⁽⁸⁰⁾. Conversely, it was reported that ingestion of leucine alone failed to stimulate MPS in the absence of a full EAA profile in postmenopausal (aged 50–65 years) women⁽⁸¹⁾. Bell *et al.* reported that with 12 weeks of combined RET (about 80% 1-repetition maximum (1-RM)) and high-intensity interval training (about 90% maximal heart-rate), alongside consumption of a multi-ingredient supplement (consisting of 30 g whey protein, 2.5 g creatine, 500 IU vitamin D, 400 mg calcium and 1500 mg *n*-3 PUFA), myofibrillar fractional synthesis rate post-training was elevated by about 30% and 7% at 0–24 and 24–48 h, respectively; however, the control group demonstrated about 20% increase in MPS compared to resting levels 24–48 h post-training⁽⁸²⁾. Therefore, it is inconclusive whether standalone or adjuvant supplementation of leucine is effective to sufficiently stimulate MPS across populations, and it remains to be investigated whether submaximal doses of complete protein enriched with leucine (at least 3 g⁽³⁹⁾) or multi-ingredient supplementation may lead to enhanced muscle anabolism in older adults⁽⁷³⁾.

Similar to protein feeding, there is evidence of anabolic resistance in response to exercise in older age. Kumar *et al.* demonstrated at 1–2 h post-RET (20–90% 1-RM), that MPS responses were blunted in older compared to younger adults⁽⁸³⁾, and with Fry *et al.* highlighting impaired skeletal muscle mTORC1 signalling (a possible mechanism underlying age-related blunting of MPS) and MPS up to 24 h post-exercise⁽⁸⁴⁾. Brook *et al.* also highlighted the presence of anabolic resistance following 6 weeks of unilateral leg RET (75% 1-RM), with MPS becoming elevated after 3 weeks in young (1.6 (SEM 0.01) % daily) but not older (1.49 (SEM 0.08) % daily) adults, which was coupled with an absence of

high fat-free mass gains in older muscle⁽⁷⁴⁾. Similarly, Durham *et al.* reported a reduced sensitivity to AA following endurance type (i.e. walking) exercise at about 40% $\text{VO}_{2\text{peak}}$ in older compared to younger adults⁽⁸⁵⁾. In contrast, Symons *et al.* reported a 50% increase in MPS in young and older muscle when exercise was coupled to a 30 g protein meal⁽³⁶⁾, suggesting aged muscle simply exhibits delays in the anabolic response to exercise coupled to nutrition⁽⁸⁶⁾. In terms of exercise intensity, it has been suggested that low-intensity high-volume RET may have comparative effects to high-intensity low-volume RET, a modality which would be of particular practicable benefit to older individuals⁽²²⁾. Indeed, results from Fry *et al.* highlight, in older compared to young adults, low-intensity RET (20% 1-RM) coupled with blood flow occlusion heightened mTORC1 signalling and MPS by 56% above basal levels 3 h post-exercise⁽⁸⁴⁾. However, in the absence of blood flow occlusion, MPS remained unchanged post-exercise⁽⁸⁴⁾. Interestingly, although in younger adults, it was demonstrated that unilateral leg extension exercise at 30% v. 90% 1-RM to failure was more effective at increasing and maintaining elevated MPS (199%) 24 h post-exercise⁽⁸⁷⁾. If RET volume rather than intensity is key for stimulating MPS, a greater portion of older adults may be able to perform RET due to associated sarcopenic comorbidities (e.g. arthritis) which may limit the performance of high-intensity exercise⁽²²⁾; thus offering a potential effective intervention to offset the impact of anabolic resistance and age-related muscle functional declines, although this requires further investigation.

Physical inactivity induces a premature muscle full state in response to dietary protein

Physical inactivity, such as sedentarism or immobilisation due to bed-rest, induces a premature muscle full state characterised by blunted fasted and fed-state MPS (i.e. anabolic resistance)^(88–93), prompting insulin resistance⁽⁹⁴⁾ and muscle atrophy⁽⁶⁾, which over time may play a key role in the aetiology of sarcopenia⁽⁹⁵⁾. In certain cases, inactivity-induced atrophy is not fully recovered despite resumption of normal ambulation⁽⁹⁶⁾ or even following RET⁽⁹⁷⁾. As such, protein intervention, as a means to stimulate inactivity-induced declines in MPS, is a primary research avenue for offsetting inactivity-induced atrophy, particularly since modulating the type⁽⁹⁸⁾ and amount⁽⁹⁹⁾ of dietary protein can somewhat overcome anabolic resistance in ageing^(98,99).

To date, results surrounding the anabolic efficacy of protein feeding during inactivity have been mixed. For example, provision of 20 g protein daily (on top of a partially controlled diet 1 g/kg/d) during 14 d of unilateral leg immobilisation did not attenuate muscle loss in middle-aged adults⁽¹⁰⁰⁾. More recently, a high protein diet (1.6 g protein/kg/d) provided at evenly spaced intervals throughout the day (strategically done so in order to avoid the refractory period), was shown to have no positive influence on MPS or muscle volume observed with 3 d of unilateral limb immobilisation in young males⁽¹⁰¹⁾.

This led the authors to suggest that dietary protein consumption of ≤ 1.6 g/kg/d during inactivity does not modulate muscle loss⁽¹⁰¹⁾, perhaps calling for future studies to investigate whether larger protein doses can overcome the anabolic resistance that manifests during inactivity. On the contrary, higher dose EAA/leucine supplementation has shown more promising results. For example, high-dose EAA combined with carbohydrate during 28 d of bed-rest preserved MPS rates and ameliorated the loss of lean muscle mass^(102,103). Further, middle-aged adults consuming leucine supplementation (0.06 g/kg/meal) during 14 d of bed rest illustrated attenuated reductions in post-absorptive MPS and reduced whole-body lean mass loss after 7 d (compared to an alanine control group)⁽¹⁰⁴⁾. However, not all studies are in agreement; 7.5 g/d of free leucine did not attenuate muscle mass declines in young adults undergoing 7 d of unilateral limb immobilisation⁽¹⁰⁵⁾. Whilst the precise cause(s) of discrepancies between study findings are unknown, the model of inactivity used (i.e. bed rest, unilateral limb immobilisation), volunteer characteristics, dietary control within studies, and importantly, the differing amount and quality of protein provided are likely factors. In line with the general consensus of the literature thus far, it is plausible that higher dose EAA/leucine, as opposed to high protein diets, may be a more effective intervention to overcome the premature onset of muscle full during inactivity. If so, it has been suggested that it is not the availability of AA *per se* that is limiting muscle anabolism during inactivity, but rather inactivity induces a significant increase in the threshold required for EAA/leucine to stimulate anabolism (e.g. intracellular signalling pathways)⁽¹⁰¹⁾. To test this, future research should thus focus on protein strategies that maximise intracellular transport and delivery of AA, therein maximising anabolic signals during inactivity⁽¹⁰¹⁾. In the search for alternative/effective protein therapeutics, NEAA (which seemingly play a trivial role in healthy muscle⁽¹⁰⁶⁾), may be important in ameliorating inactivity-induced muscle decline⁽¹⁰⁷⁾. For example, glutamine is purported to harbour anti-catabolic properties⁽¹⁰⁸⁾ while arginine is implicated in the maintenance of muscle perfusion⁽¹⁰⁹⁾ contributing to substrate delivery or MPS stimulation^(107,110). As such, dietary formulations combining EAA and NEAA may confer unique mechanistic advantages over either AA profile in isolation due to the simultaneous targeting and therapizing of multiple inactivity-activated molecular processes contributing to muscle decline. Indeed, a novel AA formulation (AXA2678) containing select anabolic EAA (e.g. leucine) and NEAA (glutamine, arginine and n-acetylcysteine) consumed thrice daily, preserved muscle volume and cross-sectional area during 7 d of immobilisation in young men⁽¹⁰⁷⁾. However, a confounder within this study was the use of a carbohydrate placebo, meaning the treatment group (AXA2678) received an additional about 66.8 g AA daily, maybe explaining the positive findings⁽¹⁰⁷⁾. Future studies are warranted that compare supplements such as AXA2678 to appropriate controls, and to test their efficacy in situations of anabolic resistance (i.e. ageing).




Fig. 1. Summary of skeletal muscle proteostasis in relation to dietary protein, exercise, ageing and physical inactivity. (A) Skeletal muscle atrophy is a prominent feature of many pathological conditions, associating with a multitude of negative outcomes, (B) the essential amino acid (EAA) and branched-chain amino acid (BCAA), leucine (LEU), is the most anabolic constituent of protein feeding, where amino acids (AA) act as signals and substrates for the transient and purportedly dose-dependent regulation of muscle protein synthesis (MPS), (C) small (about 3 g) quantities of LEU elicit robust MPS and so, it is likely that the MPS response to protein/EAA is not driven by AA quantity *per se* but instead by the LEU content, (D) protein/LEU feeding in combination with exercise (resistance exercise (RE)) delays the onset of muscle full, (E) anabolic resistance contributes to age-related muscle atrophy, which may be (partially) overcome by EAA/LEU supplementation and RE and (F) physical inactivity (e.g. bed rest, immobilisation) induces a premature onset of muscle full, which may be circumvented by high EAA/LEU supplementation, muscle contraction (e.g. neuromuscular electrical stimulation) and/or non-essential amino acids (NEAA). Akt, protein kinase B; eIF4E, eukaryotic initiation factor 4E; EX, exercise; ICU, intensive care unit; LEAA, leucine-rich essential amino acids; mTORC1, mechanistic target of rapamycin complex 1; O, older adults; PA, physical activity; PI, physical inactivity; PRO, protein; S6K1, ribosomal protein S6 kinase; T2DM, type II diabetes mellitus; WP, whey protein; Y, young adults; 4EBP1, 4E-binding protein.

A parallel anabolic intervention to protein feeding in order to negate the premature onset of muscle full during inactivity is the re-introduction of some form of muscle contraction during the period of inactivity^(111,112). For example, RE performed every other day during 14 d bed rest or immobilisation in young adults prevented declines in type I and II myofibres⁽¹¹¹⁾ and muscle cross-sectional area⁽¹¹²⁾, respectively. However, the ability to perform exercise during inactivity, both in the context of physical capacity and having access to an appropriate environment (e.g. equipment and expertise) are key considerations for this type of intervention, particularly in a clinical setting. In light of this, some researchers have applied neuromuscular electrical stimulation which, from a practical standpoint, has many benefits such as its relatively low cost, ease for hospital staff to apply, tolerance of volunteers, and no reported contraindications or side effects, and importantly, it is feasible and applicable during situations of inactivity or incapacity⁽¹¹³⁾. Indeed, neuromuscular electrical stimulation prevented declines in quadriceps cross-sectional area in young healthy males following 5 d unilateral leg immobilisation,

with corresponding attenuations in the atrophy-associated markers, myostatin and muscle atrophy F-box⁽¹¹⁴⁾. However, the interactions of neuromuscular electrical stimulation and protein feeding in the context of inactivity remain to be investigated, and across populations. Thus, whilst inactivity-activity-protein interactions show tremendous potential for mitigating inactivity-associated muscle decline, studies are still very much in the infancy stage, even more so in the context of a young clinical setting (e.g. hospitalisation).

Dietary protein to mitigate the premature muscle full state during physical inactivity in ageing

From a clinical perspective, older adults are more likely to experience bouts of inactivity (e.g. hospitalisation/physical debilitation with ensuing bed rest)^(97,115), with most hospitalised patients over 65 years old and having longer lengths of hospital stays⁽¹¹⁶⁾. This may induce acute sarcopenia. Indeed, the associated loss of muscle mass is significant and rapid, with older adults losing

detectable muscle mass (about 1.5%) within as few as 5 d unilateral limb immobilisation⁽¹¹⁷⁾ and losing up to about 6% (about 1 kg) of lean mass during 10 d bed rest⁽¹¹⁸⁾; this is purportedly greater than the loss of muscle seen in younger subjects following 14 or 28 d bed rest^(103,119). In older individuals, the premature onset of muscle full associated with inactivity may be further confounded by age-related anabolic resistance to nutrition. As such, ageing populations subjected to periods of physical inactivity stand to benefit considerably from optimised dietary protein–exercise intervention.

As with younger adults, the ability of protein feeding in older adults to offset the premature muscle full state associated with inactivity has produced mixed results. For example, twice daily supplementation of protein (20.7 g), fat (3.0 g) and carbohydrate (9.3 g) on top of an ample protein diet (1.1 g/kg/d) during 5 d unilateral leg immobilisation did not attenuate muscle mass declines in older males⁽¹¹⁷⁾. This led the authors to speculate that maintaining dietary protein intake is necessary to prevent muscle loss during inactivity, but hyper-protein consumption would not further circumvent muscle loss⁽¹¹⁷⁾, although more recent data from the same group obtained in younger adults no longer supports this hypothesis⁽¹⁰¹⁾. Further studies show that high-dose EAA supplementation (15 g thrice daily) on top of a diet containing 0.8 g/kg/d protein attenuated the decline in 24 h fractional synthesis rate during 10 d bed rest in older adults⁽¹²⁰⁾. Similarly, healthy older men and women consuming daily meals supplemented with leucine (3–4 g/meal) during 7 d bed rest reduced the loss of leg lean mass (compared to alanine control)⁽¹¹⁵⁾. This demonstrates the anabolic potential of small amounts of supplemental leucine and highlights practical advantages such as the cost and ease of incorporating leucine into meal plans⁽¹¹⁵⁾. Although muscle loss is largely attributed to marked declines in MPS, potential undetectable changes in MPB cannot be disregarded; particularly in cohorts where the MPB response to inactivity is not well characterised (i.e. older adults),

most likely due to difficulties surrounding MPB-related methodologies. As such, HMB has been tested as a potential therapeutic in inactive older adults due to its pro-anabolic and anti-catabolic properties⁽³⁹⁾ and its efficacy for preserving older muscle health in the context of habitual living⁽¹²¹⁾. In these trials, older men and women consuming 3 g/d HMB during bed rest confinement for 10 d maintained MPS rates pre- to post-bed rest and preserved muscle mass (control volunteers lost about 2 kg lean mass)⁽¹²²⁾. As such, data thus far in older adults echo that of the young, where EAA/leucine, and possibly HMB, may demonstrate greater anabolic effects during inactivity, compared to high protein diets. As a collective, these studies demonstrate there is potential for refined nutritional interventions to offset inactivity-induced atrophy in ageing.

Considering protein feeding in isolation may not fully counteract the premature onset of muscle full during inactivity in older adults; adjunct interventions, such as clinically relevant, feasible (i.e. financially) and effective exercise interventions, are needed. Importantly, hospitalised older adults experience functional decline and are often limited to about 4 min walking every 3 h, which is even less so in women who typically engage in about 2 min walking every 3 h⁽¹²³⁾. As such, neuromuscular electrical stimulation is a logical adjunct intervention that is (as previously discussed) clinically feasible even for those who are totally incapable of weight bearing. Investigations thus far have shown that following 1 d bed rest, older adults subjected to unilateral neuromuscular electrical stimulation followed by 40 g casein ingestion prior to sleep led to an about 18% greater increase in MPS overnight (compared to the unstimulated leg)⁽¹¹³⁾. In the context of longer periods of inactivity, 5 d bed rest combined with neuromuscular electrical stimulation (40 min, thrice daily) and supplemental protein (17 g/d) maintained thigh lean mass and attenuated increases in catabolic biomarkers, myostatin and muscle atrophy F-box, perhaps (at least partly) underlying the preservation of lean mass observed in this trial⁽¹²⁴⁾.

Table 1. Key research gaps surrounding dietary protein, exercise, ageing and physical inactivity in relation to skeletal muscle proteostasis

| |
|--|
| Protein |
| Identification of the precise AA sensor(s) coupling intracellular AA to mTORC1 signalling |
| Uncover the mechanisms underlying the ‘switch’ from stimulated MPS back to fasting MPS in the face of continued AA availability and mTORC1 activity (i.e. mechanisms regulating muscle full) |
| Discover how long is required after maximal MPS stimulation, before the next stimulation of MPS is possible (i.e. refractory period kinetics) |
| Exercise |
| What minimum threshold of combined exercise (i.e. type, duration, intensity) and protein (i.e. type, amount) is required to delay muscle full? |
| What combination of exercise (i.e. type, duration, intensity) and protein (i.e. type, amount) can minimise the refractory period? |
| Ageing |
| Investigate the additive anabolic effects of optimal RET volume/intensity and optimal protein nutrition to overcome anabolic resistance |
| Physical inactivity |
| Establish the optimal protein quantity to maximally stimulate MPS during inactivity, across age |
| Impact of novel protein supplements (e.g. AXA2678) on MPS, in the context of physical inactivity and ageing |
| Better understand the impacts of physical inactivity in clinical populations (i.e. hospitalised patients as opposed to healthy volunteers, ±inflammation) |
| Investigate protein–exercise interactions in young healthy and clinical populations undergoing periods of inactivity (i.e. ±inflammation) |
| Devise protein–exercise interactions that specifically target older female clinical populations undergoing periods of inactivity |

AA, amino acids; MPS, muscle protein synthesis; mTORC1, mechanistic target of rapamycin complex 1; RET, resistance exercise training.

Protein–exercise interventional approaches such as this may have translational ramifications for preserving muscle anabolic responses in older adults subjected to periods of inactivity in a clinical setting (i.e. hospitalisation). Future studies should aim to optimise such ‘EX-NUT’ interventions, particularly in women, considering apparent sexual dimorphism in ambulation in hospital settings.

It should be noted that whilst inactivity studies (i.e. bed rest, immobilisation, reduced physical activity) in healthy young and older volunteer populations allow for the metabolic and molecular investigations of inactivity-induced muscle decline, whilst controlling for lifestyle factors that can drastically influence metabolism (e.g. diet, activity, etc.), clinical translation must be treated with caution. For example, the onset of illness or occurrence of injury often results in hospital admittance where a hyper-metabolism (or other catabolic stressors such as inflammation) may result in excessive or accelerated muscle loss, particularly in those with comorbidities, which may have specific dietary challenges and requirements⁽¹²⁵⁾ and, importantly, may not be recapitulated in healthy research volunteers⁽⁷³⁾. As such, investigations into the effects of protein nutrition in both young and older clinical populations undergoing inactivity are imminently needed in order to optimise appropriate anabolic interventions. Furthermore, in an attempt to effectively and fully translate clinical trials into the clinical setting, it is imperative that day-to-day concerns, such as the quantity, taste and palatability of protein feeding⁽¹²⁵⁾ and tolerability and compliance to exercise interventions are thoroughly trialled in appropriate clinical populations.

Conclusion

In summary (Fig. 1), dietary protein is a pre-requisite for the day-to-day maintenance of skeletal muscle mass, supported through the stimulation of MPS and attenuation of MPB. The anabolic effects of dietary protein are driven mainly by EAA, particularly leucine, and are transient in nature (lasting about 2–3 h). This muscle full state cannot be overcome by further feeding meaning a refractory period must exist before the next MPS stimulation is possible. However, muscle full can be delayed by exercise via increased sensitivity of muscle to EAA extending the duration of MPS, whereas ageing/inactivity are associated with a blunted synthetic response to exercise/protein feeding (anabolic resistance) resulting in a premature onset of muscle full. In an attempt to promote the translation of the currently available evidence, we provide the following frameworks that we believe may help delay muscle full or negate the premature onset in each given scenario; (i) in conjunction with a bout of RE, 20 g protein/low-dose leucine-enriched EAA (3 g, 40% leucine) should be consumed, although these protein recommendations may need to be increased in the context of whole body RE, (ii) in older adults, greater quantities of protein (about 40 g)/fortifying protein with leucine (about 3 g) should be consumed each

meal in conjunction with performing optimal RE, and (iii) in situations of physical inactivity (and physical inactivity during ageing), heightened EAA/leucine (as opposed to high protein diets) supplementation, potentially in combination with NEAA cocktails, should be consumed alongside some form of muscle contraction (e.g. neuromuscular electrical stimulation), if physically/logistically possible to do so. Despite the substantial body of research to date, it is clear that a number of gaps remain in our understanding of how dietary protein, exercise, ageing and physical inactivity influence skeletal muscle proteostasis, and so we direct and encourage our target audience to refer to Table 1, which highlights (what we regard as) important research questions worthy of future robust clinical trial investigation/s.

Financial Support

This work was supported by the Medical Research Council (grant number MR/P021220/1) as part of the MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research awarded to the Universities of Nottingham and Birmingham, and supported by the NIHR Nottingham Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. C. S. D. is a funded Medical Research Council Skills Development Fellow (MR/T026014/1).

Conflict of Interest

P. J. A. has received research funding from Ajinomoto, Abbott Nutrition and Fresenius-Kabi.

Authorship

All authors wrote and approved the manuscript.

References

1. Rosenberg IH (1997) Sarcopenia: origins and clinical relevance. *J Nutr* **127**, 990S–991S.
2. Aversa Z, Costelli P & Muscaritoli M (2017) Cancer-induced muscle wasting: latest findings in prevention and treatment. *Ther Adv Med Oncol* **9**, 369–382.
3. Sala D & Zorzano A (2015) Differential control of muscle mass in type 1 and type 2 diabetes mellitus. *Cell Mol Life Sci* **72**, 3803–3817.
4. Challal S, Minichiello E, Boissier MC *et al.* (2016) Cachexia and adiposity in rheumatoid arthritis. Relevance for disease management and clinical outcomes. *Joint Bone Spine* **83**, 127–133.
5. Breen L, Stokes KA, Churchward-Venne TA *et al.* (2013) Two weeks of reduced activity decreases leg lean mass and induces ‘anabolic resistance’ of myofibrillar protein synthesis in healthy elderly. *J Clin Endocrinol Metab* **98**, 2604–2612.
6. Kilroe SP, Fulford J, Holwerda AM *et al.* (2020) Short-term muscle disuse induces a rapid and sustained

- decline in daily myofibrillar protein synthesis rates. *Am J Physiol Endocrinol Metab* **318**, E117–E130.
7. Wolfe RR (2006) The underappreciated role of muscle in health and disease. *Am J Clin Nutr* **84**, 475–482.
 8. Guo Z, Burguera B & Jensen MD (2000) Kinetics of intramuscular triglyceride fatty acids in exercising humans. *J Appl Physiol* (1985) **89**, 2057–2064.
 9. Ivy JL, Katz AL, Cutler CL *et al.* (1988) Muscle glycogen synthesis after exercise: effect of time of carbohydrate ingestion. *J Appl Physiol* (1985) **64**, 1480–1485.
 10. Brook MS, Wilkinson DJ & Atherton PJ (2020) An update on nutrient modulation in the management of disease-induced muscle wasting: evidence from human studies. *Curr Opin Clin Nutr Metab Care* **23**, 174–180.
 11. Atherton PJ, Greenhaff PL, Phillips SM *et al.* (2016) Control of skeletal muscle atrophy in response to disuse: clinical/preclinical contentions and fallacies of evidence. *Am J Physiol Endocrinol Metab* **311**, E594–604.
 12. Prado CM, Purcell SA, Alish C *et al.* (2018) Implications of low muscle mass across the continuum of care: a narrative review. *Ann Med* **50**, 675–693.
 13. Luukinen H, Koski K, Laippala P *et al.* (1997) Factors predicting fractures during falling impacts among home-dwelling older adults. *J Am Geriatr Soc* **45**, 1302–1309.
 14. Cruz-Jentoft AJ, Baeyens JP, Bauer JM *et al.* (2010) Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing* **39**, 412–423.
 15. Laukkanen P, Heikkinen E & Kauppinen M (1995) Muscle strength and mobility as predictors of survival in 75–84-year-old people. *Age Ageing* **24**, 468–473.
 16. Atherton PJ & Smith K (2012) Muscle protein synthesis in response to nutrition and exercise. *J Physiol* **590**, 1049–1057.
 17. Gorissen SHM & Witard OC (2018) Characterising the muscle anabolic potential of dairy, meat and plant-based protein sources in older adults. *Proc Nutr Soc* **77**, 20–31.
 18. Deane CS, Bass JJ, Crossland H *et al.* (2020) Animal, plant, collagen and blended dietary proteins: effects on musculoskeletal outcomes. *Nutrients* **12** [Epublication 1 September 2020].
 19. Gorissen SH, Remond D & van Loon LJ (2015) The muscle protein synthetic response to food ingestion. *Meat Sci* **109**, 96–100.
 20. Stokes T, Hector AJ, Morton RW *et al.* (2018) Recent perspectives regarding the role of dietary protein for the promotion of muscle hypertrophy with resistance exercise training. *Nutrients* **10** [Epublication 7 February 2018].
 21. Trommelen J, Betz MW & van Loon LJC (2019) The muscle protein synthetic response to meal ingestion following resistance-type exercise. *Sports Med* **49**, 185–197.
 22. Breen L & Phillips SM (2011) Skeletal muscle protein metabolism in the elderly: interventions to counteract the ‘anabolic resistance’ of ageing. *Nutr Metab (Lond)* **8**, 68.
 23. Brook MS & Wilkinson DJ (2020) Contemporary stable isotope tracer approaches: insights into skeletal muscle metabolism in health and disease. *Exp Physiol* **105**, 1081–1089.
 24. Brook MS, Wilkinson DJ, Atherton PJ *et al.* (2017) Recent developments in deuterium oxide tracer approaches to measure rates of substrate turnover: implications for protein, lipid, and nucleic acid research. *Curr Opin Clin Nutr Metab Care* **20**, 375–381.
 25. Rennie MJ (1999) An introduction to the use of tracers in nutrition and metabolism. *Proc Nutr Soc* **58**, 935–944.
 26. Wilkinson DJ, Brook MS, Smith K *et al.* (2017) Stable isotope tracers and exercise physiology: past, present and future. *J Physiol* **595**, 2873–2882.
 27. Wilkinson DJ, Cegielski J, Phillips BE *et al.* (2015) Internal comparison between deuterium oxide (D₂O) and L-[ring-13C₆] phenylalanine for acute measurement of muscle protein synthesis in humans. *Physiol Rep* **3** [Epublication 6 July 2015].
 28. Wilkinson DJ, Franchi MV, Brook MS *et al.* (2014) A validation of the application of D(2)O stable isotope tracer techniques for monitoring day-to-day changes in muscle protein subfraction synthesis in humans. *Am J Physiol Endocrinol Metab* **306**, E571–579.
 29. Rennie MJ, Edwards RH, Halliday D *et al.* (1982) Muscle protein synthesis measured by stable isotope techniques in man: the effects of feeding and fasting. *Clin Sci (Lond)* **63**, 519–523.
 30. Bennet WM, Connacher AA, Scrimgeour CM *et al.* (1989) Increase in anterior tibialis muscle protein synthesis in healthy man during mixed amino acid infusion: studies of incorporation of [1-13C]leucine. *Clin Sci (Lond)* **76**, 447–454.
 31. Smith K, Barua JM, Watt PW *et al.* (1992) Flooding with L-[1-13C]leucine stimulates human muscle protein incorporation of continuously infused L-[1-13C]valine. *Am J Physiol* **262**, E372–376.
 32. Smith K, Reynolds N, Downie S *et al.* (1998) Effects of flooding amino acids on incorporation of labeled amino acids into human muscle protein. *Am J Physiol* **275**, E73–78.
 33. Cuthbertson D, Smith K, Babraj J *et al.* (2005) Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. *FASEB J* **19**, 422–424.
 34. Moore DR, Churchward-Venne TA, Witard O *et al.* (2015) Protein ingestion to stimulate myofibrillar protein synthesis requires greater relative protein intakes in healthy older versus younger men. *J Gerontol A Biol Sci Med Sci* **70**, 57–62.
 35. Moore DR, Robinson MJ, Fry JL *et al.* (2009) Ingested protein dose response of muscle and albumin protein synthesis after resistance exercise in young men. *Am J Clin Nutr* **89**, 161–168.
 36. Symons TB, Sheffield-Moore M, Wolfe RR *et al.* (2009) A moderate serving of high-quality protein maximally stimulates skeletal muscle protein synthesis in young and elderly subjects. *J Am Diet Assoc* **109**, 1582–1586.
 37. Witard OC, Jackman SR, Breen L *et al.* (2014) Myofibrillar muscle protein synthesis rates subsequent to a meal in response to increasing doses of whey protein at rest and after resistance exercise. *Am J Clin Nutr* **99**, 86–95.
 38. Macnaughton LS, Wardle SL, Witard OC *et al.* (2016) The response of muscle protein synthesis following whole-body resistance exercise is greater following 40 g than 20 g of ingested whey protein. *Physiol Rep* **4** [Epublication 4 August 2016].
 39. Wilkinson DJ, Hossain T, Hill DS *et al.* (2013) Effects of leucine and its metabolite beta-hydroxy-beta-methylbutyrate on human skeletal muscle protein metabolism. *J Physiol* **591**, 2911–2923.
 40. Bukhari SS, Phillips BE, Wilkinson DJ *et al.* (2015) Intake of low-dose leucine-rich essential amino acids stimulates muscle anabolism equivalently to bolus whey protein in older women at rest and after exercise. *Am J Physiol Endocrinol Metab* **308**, E1056–1065.
 41. Benelam B (2009) Satiety and the anorexia of ageing. *Br J Community Nurs* **14**, 332–335.

42. Burd NA, Yang Y, Moore DR *et al.* (2012) Greater stimulation of myofibrillar protein synthesis with ingestion of whey protein isolate v. micellar casein at rest and after resistance exercise in elderly men. *Br J Nutr* **108**, 958–962.
43. Pennings B, Boirie Y, Senden JM *et al.* (2011) Whey protein stimulates postprandial muscle protein accretion more effectively than do casein and casein hydrolysate in older men. *Am J Clin Nutr* **93**, 997–1005.
44. Mitchell WK, Phillips BE, Williams JP *et al.* (2015) The impact of delivery profile of essential amino acids upon skeletal muscle protein synthesis in older men: clinical efficacy of pulse vs. bolus supply. *Am J Physiol Endocrinol Metab* **309**, E450–457.
45. Wagenmakers AJ (1998) Protein and amino acid metabolism in human muscle. *Adv Exp Med Biol* **441**, 307–319.
46. Mitchell WK, Wilkinson DJ, Phillips BE *et al.* (2016) Human skeletal muscle protein metabolism responses to amino acid nutrition. *Adv Nutr* **7**, 828S–838S.
47. Escobar J, Frank JW, Suryawan A *et al.* (2010) Leucine and alpha-ketoisocaproic acid, but not norleucine, stimulate skeletal muscle protein synthesis in neonatal pigs. *J Nutr* **140**, 1418–1424.
48. Van Koeveering M & Nissen S (1992) Oxidation of leucine and alpha-ketoisocaproate to beta-hydroxy-beta-methylbutyrate in vivo. *Am J Physiol* **262**, E27–31.
49. Wilkinson DJ, Hossain T, Limb MC *et al.* (2018) Impact of the calcium form of beta-hydroxy-beta-methylbutyrate upon human skeletal muscle protein metabolism. *Clin Nutr* **37**, 2068–2075.
50. Deane CS, Wilkinson DJ, Phillips BE *et al.* (2017) ‘Nutraceuticals’ in relation to human skeletal muscle and exercise. *Am J Physiol Endocrinol Metab* **312**, E282–E299.
51. Atherton PJ, Etheridge T, Watt PW *et al.* (2010) Muscle full effect after oral protein: time-dependent concordance and discordance between human muscle protein synthesis and mTORC1 signaling. *Am J Clin Nutr* **92**, 1080–1088.
52. Wilson GJ, Layman DK, Moulton CJ *et al.* (2011) Leucine or carbohydrate supplementation reduces AMPK and eEF2 phosphorylation and extends postprandial muscle protein synthesis in rats. *Am J Physiol Endocrinol Metab* **301**, E1236–1242.
53. Wilson GJ, Moulton CJ, Garlick PJ *et al.* (2012) Post-meal responses of elongation factor 2 (eEF2) and adenosine monophosphate-activated protein kinase (AMPK) to leucine and carbohydrate supplements for regulating protein synthesis duration and energy homeostasis in rat skeletal muscle. *Nutrients* **4**, 1723–1739.
54. Mitchell WK, Phillips BE, Hill I *et al.* (2017) Human skeletal muscle is refractory to the anabolic effects of leucine during the postprandial muscle-full period in older men. *Clin Sci (Lond)* **131**, 2643–2653.
55. Phillips BE, Atherton PJ, Varadhan K *et al.* (2014) Pharmacological enhancement of leg and muscle microvascular blood flow does not augment anabolic responses in skeletal muscle of young men under fed conditions. *Am J Physiol Endocrinol Metab* **306**, E168–176.
56. Phillips BE, Atherton PJ, Varadhan K *et al.* (2016) Acute cocoa flavanol supplementation improves muscle macro- and microvascular but not anabolic responses to amino acids in older men. *Appl Physiol Nutr Metab* **41**, 548–556.
57. Kimball SR (2014) Integration of signals generated by nutrients, hormones, and exercise in skeletal muscle. *Am J Clin Nutr* **99**, 237S–242S.
58. Wolfson RL, Chantranupong L, Saxton RA *et al.* (2016) Sestrin2 is a leucine sensor for the mTORC1 pathway. *Science* **351**, 43–48.
59. Proud CG (2009) mTORC1 signalling and mRNA translation. *Biochem Soc Trans* **37**, 227–231.
60. Proud CG (2011) mTOR signalling in health and disease. *Biochem Soc Trans* **39**, 431–436.
61. Wilkes EA, Selby AL, Atherton PJ *et al.* (2009) Blunting of insulin inhibition of proteolysis in legs of older subjects may contribute to age-related sarcopenia. *Am J Clin Nutr* **90**, 1343–1350.
62. Greenhaff PL, Karagounis LG, Peirce N *et al.* (2008) Disassociation between the effects of amino acids and insulin on signaling, ubiquitin ligases, and protein turnover in human muscle. *Am J Physiol Endocrinol Metab* **295**, E595–604.
63. Abdulla H, Smith K, Atherton PJ *et al.* (2016) Role of insulin in the regulation of human skeletal muscle protein synthesis and breakdown: a systematic review and meta-analysis. *Diabetologia* **59**, 44–55.
64. Biolo G, Maggi SP, Williams BD *et al.* (1995) Increased rates of muscle protein turnover and amino acid transport after resistance exercise in humans. *Am J Physiol* **268**, E514–520.
65. Pennings B, Koopman R, Beelen M *et al.* (2011) Exercising before protein intake allows for greater use of dietary protein-derived amino acids for de novo muscle protein synthesis in both young and elderly men. *Am J Clin Nutr* **93**, 322–331.
66. Staples AW, Burd NA, West DW *et al.* (2011) Carbohydrate does not augment exercise-induced protein accretion versus protein alone. *Med Sci Sports Exerc* **43**, 1154–1161.
67. Burd NA, West DW, Moore DR *et al.* (2011) Enhanced amino acid sensitivity of myofibrillar protein synthesis persists for up to 24 h after resistance exercise in young men. *J Nutr* **141**, 568–573.
68. Wilkinson DJ, Piasecki M & Atherton PJ (2018) The age-related loss of skeletal muscle mass and function: measurement and physiology of muscle fibre atrophy and muscle fibre loss in humans. *Ageing Res Rev* **47**, 123–132.
69. Welle S, Thornton C, Jozefowicz R *et al.* (1993) Myofibrillar protein synthesis in young and old men. *Am J Physiol* **264**, E693–698.
70. Welle S, Thornton C & Statt M (1995) Myofibrillar protein synthesis in young and old human subjects after three months of resistance training. *Am J Physiol* **268**, E422–427.
71. Phillips BE, Hill DS & Atherton PJ (2012) Regulation of muscle protein synthesis in humans. *Curr Opin Clin Nutr Metab Care* **15**, 58–63.
72. Wall BT, Gorissen SH, Pennings B *et al.* (2015) Aging is accompanied by a blunted muscle protein synthetic response to protein ingestion. *PLoS ONE* **10**, e0140903.
73. Marshall RN, Smeuninx B, Morgan PT *et al.* (2020) Nutritional strategies to offset disuse-induced skeletal muscle atrophy and anabolic resistance in older adults: from whole-foods to isolated ingredients. *Nutrients* **12** [Epublication 25 May 2020].
74. Brook MS, Wilkinson DJ, Mitchell WK *et al.* (2016) Synchronous deficits in cumulative muscle protein synthesis and ribosomal biogenesis underlie age-related anabolic resistance to exercise in humans. *J Physiol* **594**, 7399–7417.
75. Mitchell WK, Williams J, Atherton P *et al.* (2012) Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. *Front Physiol* **3**, 260.

76. Chevalier S, Goulet ED, Burgos SA *et al.* (2011) Protein anabolic responses to a fed steady state in healthy aging. *J Gerontol A Biol Sci Med Sci* **66**, 681–688.
77. Bauer J, Biolo G, Cederholm T *et al.* (2013) Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. *J Am Med Dir Assoc* **14**, 542–559.
78. Atherton PJ, Kumar V, Selby AL *et al.* (2017) Enriching a protein drink with leucine augments muscle protein synthesis after resistance exercise in young and older men. *Clin Nutr* **36**, 888–895.
79. Jackman SR, Witard OC, Philp A *et al.* (2017) Branched-chain amino acid ingestion stimulates muscle myofibrillar protein synthesis following resistance exercise in humans. *Front Physiol* **8**, 390.
80. Fuchs CJ, Hermans WJH, Holwerda AM *et al.* (2019) Branched-chain amino acid and branched-chain ketoacid ingestion increases muscle protein synthesis rates in vivo in older adults: a double-blind, randomized trial. *Am J Clin Nutr* **110**, 862–872.
81. van Vliet S, Smith GI, Porter L *et al.* (2018) The muscle anabolic effect of protein ingestion during a hyperinsulinaemic euglycaemic clamp in middle-aged women is not caused by leucine alone. *J Physiol* **596**, 4681–4692.
82. Bell KE, Brook MS, Snijders T *et al.* (2019) Integrated myofibrillar protein synthesis in recovery from unaccustomed and accustomed resistance exercise with and without multi-ingredient supplementation in overweight older men. *Front Nutr* **6**, 40.
83. Kumar V, Selby A, Rankin D *et al.* (2009) Age-related differences in the dose-response relationship of muscle protein synthesis to resistance exercise in young and old men. *J Physiol* **587**, 211–217.
84. Fry CS, Glynn EL, Drummond MJ *et al.* (2010) Blood flow restriction exercise stimulates mTORC1 signaling and muscle protein synthesis in older men. *J Appl Physiol* (1985) **108**, 1199–1209.
85. Durham WJ, Casperson SL, Dillon EL *et al.* (2010) Age-related anabolic resistance after endurance-type exercise in healthy humans. *FASEB J* **24**, 4117–4127.
86. Drummond MJ, Glynn EL, Fry CS *et al.* (2010) An increase in essential amino acid availability upregulates amino acid transporter expression in human skeletal muscle. *Am J Physiol Endocrinol Metab* **298**, E1011–1018.
87. Burd NA, West DW, Staples AW *et al.* (2010) Low-load high volume resistance exercise stimulates muscle protein synthesis more than high-load low volume resistance exercise in young men. *PLoS ONE* **5**, e12033.
88. de Boer MD, Selby A, Atherton P *et al.* (2007) The temporal responses of protein synthesis, gene expression and cell signalling in human quadriceps muscle and patellar tendon to disuse. *J Physiol* **585**, 241–251.
89. Glover EI, Phillips SM, Oates BR *et al.* (2008) Immobilization induces anabolic resistance in human myofibrillar protein synthesis with low and high dose amino acid infusion. *J Physiol* **586**, 6049–6061.
90. McGlory C, Gorissen SHM, Kamal M *et al.* (2019) Omega-3 fatty acid supplementation attenuates skeletal muscle disuse atrophy during two weeks of unilateral leg immobilization in healthy young women. *FASEB J* **33**, 4586–4597.
91. Shad BJ, Thompson JL, Holwerda AM *et al.* (2019) One week of step reduction lowers myofibrillar protein synthesis rates in young men. *Med Sci Sports Exerc* **51**, 2125–2134.
92. Wall BT, Dirks ML, Snijders T *et al.* (2016) Short-term muscle disuse lowers myofibrillar protein synthesis rates and induces anabolic resistance to protein ingestion. *Am J Physiol Endocrinol Metab* **310**, E137–147.
93. Wall BT, Snijders T, Senden JM *et al.* (2013) Disuse impairs the muscle protein synthetic response to protein ingestion in healthy men. *J Clin Endocrinol Metab* **98**, 4872–4881.
94. Dirks ML, Wall BT, van de Valk B *et al.* (2016) One week of bed rest leads to substantial muscle atrophy and induces whole-body insulin resistance in the absence of skeletal muscle lipid accumulation. *Diabetes* **65**, 2862–2875.
95. Wall BT, Dirks ML, van Loon LJ (2013) Skeletal muscle atrophy during short-term disuse: implications for age-related sarcopenia. *Ageing Res Rev* **12**, 898–906.
96. McGlory C, von Allmen MT, Stokes T *et al.* (2018) Failed recovery of glycemic control and myofibrillar protein synthesis with 2 wk of physical inactivity in overweight, prediabetic older adults. *J Gerontol A Biol Sci Med Sci* **73**, 1070–1077.
97. Suetta C, Hvid LG, Justesen L *et al.* (2009) Effects of aging on human skeletal muscle after immobilization and retraining. *J Appl Physiol* (1985) **107**, 1172–1180.
98. Pennings B, Groen BB, van Dijk JW *et al.* (2013) Minced beef is more rapidly digested and absorbed than beef steak, resulting in greater postprandial protein retention in older men. *Am J Clin Nutr* **98**, 121–128.
99. Pennings B, Groen B, de Lange A *et al.* (2012) Amino acid absorption and subsequent muscle protein accretion following graded intakes of whey protein in elderly men. *Am J Physiol Endocrinol Metab* **302**, E992–999.
100. Mitchell CJ, D'Souza RF, Mitchell SM *et al.* (2018) Impact of dairy protein during limb immobilization and recovery on muscle size and protein synthesis; a randomized controlled trial. *J Appl Physiol* (1985) **124**, 717–728.
101. Kilroe SP, Fulford J, Jackman S *et al.* (2020) Dietary protein intake does not modulate daily myofibrillar protein synthesis rates or loss of muscle mass and function during short-term immobilization in young men: a randomized controlled trial. *Am J Clin Nutr* [Epublication ahead of print version].
102. Paddon-Jones D, Sheffield-Moore M, Urban RJ *et al.* (2005) The catabolic effects of prolonged inactivity and acute hypercortisolemia are offset by dietary supplementation. *J Clin Endocrinol Metab* **90**, 1453–1459.
103. Paddon-Jones D, Sheffield-Moore M, Urban RJ *et al.* (2004) Essential amino acid and carbohydrate supplementation ameliorates muscle protein loss in humans during 28 days bedrest. *J Clin Endocrinol Metab* **89**, 4351–4358.
104. English KL, Mettler JA, Ellison JB *et al.* (2016) Leucine partially protects muscle mass and function during bed rest in middle-aged adults. *Am J Clin Nutr* **103**, 465–473.
105. Backx EMP, Horstman AMH, Marzuca-Nassr GN *et al.* (2018) Leucine supplementation does not attenuate skeletal muscle loss during leg immobilization in healthy, young men. *Nutrients* **10** [Epublication 17 May 2018].
106. Davies RW, Bass JJ, Carson BP *et al.* (2019) Differential stimulation of post-exercise myofibrillar protein synthesis in humans following isonitrogenous, isocaloric pre-exercise feeding. *Nutrients* **11** [Epublication 19 July 2019].
107. Holloway TM, McGlory C, McKellar S *et al.* (2019) A novel amino acid composition ameliorates short-term muscle disuse atrophy in healthy young men. *Front Nutr* **6**, 105.
108. Nishizaki K, Ikegami H, Tanaka Y *et al.* (2015) Effects of supplementation with a combination of beta-hydroxy-beta-methyl butyrate, L-arginine, and L-glutamine on postoperative recovery of quadriceps muscle strength



- after total knee arthroplasty. *Asia Pac J Clin Nutr* **24**, 412–420.
109. Mitchell WK, Phillips BE, Wilkinson DJ *et al.* (2017) Supplementing essential amino acids with the nitric oxide precursor, l-arginine, enhances skeletal muscle perfusion without impacting anabolism in older men. *Clin Nutr* **36**, 1573–1579.
110. Chantranupong L, Scaria SM, Saxton RA *et al.* (2016) The CASTOR proteins are arginine sensors for the mTORC1 pathway. *Cell* **165**, 153–164.
111. Bamman MM, Clarke MS, Feeback DL *et al.* (1998) Impact of resistance exercise during bed rest on skeletal muscle sarcopenia and myosin isoform distribution. *J Appl Physiol* (1985) **84**, 157–163.
112. Oates BR, Glover EI, West DW *et al.* (2010) Low-volume resistance exercise attenuates the decline in strength and muscle mass associated with immobilization. *Muscle Nerve* **42**, 539–546.
113. Dirks ML, Groen BB, Franssen R *et al.* (2017) Neuromuscular electrical stimulation prior to presleep protein feeding stimulates the use of protein-derived amino acids for overnight muscle protein synthesis. *J Appl Physiol* (1985) **122**, 20–27.
114. Dirks ML, Wall BT, Snijders T *et al.* (2014) Neuromuscular electrical stimulation prevents muscle disuse atrophy during leg immobilization in humans. *Acta Physiol (Oxf)* **210**, 628–641.
115. Arentson-Lantz EJ, Fiebig KN, Anderson-Catania KJ *et al.* (2020) Countering disuse atrophy in older adults with low-volume leucine supplementation. *J Appl Physiol* (1985) **128**, 967–977.
116. He W, Sengupta M, Velkoff VA *et al.* (2005) *65+ in the United States: 2005*. Current Population Reports.
117. Dirks ML, Wall BT, Nilwik R *et al.* (2014) Skeletal muscle disuse atrophy is not attenuated by dietary protein supplementation in healthy older men. *J Nutr* **144**, 1196–1203.
118. Kortebein P, Ferrando A, Lombeida J *et al.* (2007) Effect of 10 days of bed rest on skeletal muscle in healthy older adults. *JAMA* **297**, 1772–1774.
119. Ferrando AA, Lane HW, Stuart CA *et al.* (1996) Prolonged bed rest decreases skeletal muscle and whole body protein synthesis. *Am J Physiol* **270**, E627–633.
120. Ferrando AA, Paddon-Jones D, Hays NP *et al.* (2010) EAA Supplementation to increase nitrogen intake improves muscle function during bed rest in the elderly. *Clin Nutr* **29**, 18–23.
121. Flakoll P, Sharp R, Baier S *et al.* (2004) Effect of beta-hydroxy-beta-methylbutyrate, arginine, and lysine supplementation on strength, functionality, body composition, and protein metabolism in elderly women. *Nutrition* **20**, 445–451.
122. Deutz NE, Pereira SL, Hays NP *et al.* (2013) Effect of beta-hydroxy-beta-methylbutyrate (HMB) on lean body mass during 10 days of bed rest in older adults. *Clin Nutr* **32**, 704–712.
123. Mahoney JE (1999) Gender differences in hallway ambulation by older adults hospitalized for medical illness. *WMJ* **98**, 40–43.
124. Reidy PT, McKenzie AI, Bruncker P *et al.* (2017) Neuromuscular electrical stimulation combined with protein ingestion preserves thigh muscle mass but not muscle function in healthy older adults during 5 days of bed rest. *Rejuvenation Res* **20**, 449–461.
125. Phillips SM, Paddon-Jones D, Layman DK (2020) Optimizing adult protein intake during catabolic health conditions. *Adv Nutr* **11**, S1058–S1069.